Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019?
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04757272|
Recruitment Status : Recruiting
First Posted : February 17, 2021
Last Update Posted : March 16, 2021
|Condition or disease|
|Corona Virus Infection Hepatitis|
The interaction of severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) and the renin angiotensin system (RAS) via angiotensin converting enzyme-2 (ACE-2), the receptor used by the SARS-CoV-2 to gain access to cells could provide an explanation for the several unusual clinical findings observed in COVID-19 Although chronic hepatitis is one of the risk factors listed by WHO for severe COVID-19, low incidence of COVID-19 was observed among HCV patients admitted to Egyptian hospitals.
Modulation of the RAS by the chronic hepatitis C virus treatment either by (ACEI or ARBS), (Daclatasvir and Sofosbuvir), (Daclatasvir and Sofosbuvir plus Ribavirin), or (Ribavirin and Interferon) protocols could give an explanation for the low incidence of COVID-19 among Egyptian population. Adding it may play a role in COVID 19 prophylaxis.
|Study Type :||Observational|
|Estimated Enrollment :||1150 participants|
|Official Title:||Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019 (COVID-19)?|
|Actual Study Start Date :||May 1, 2020|
|Estimated Primary Completion Date :||March 30, 2021|
|Estimated Study Completion Date :||April 30, 2021|
- incidence of chronic hepatitis C among COVID-19 hospitalized patients. [ Time Frame: 7 months ]incidence of chronic hepatitis C among COVID-19 hospitalized patients.
- the impact of previous exposure to different HCV management protocols on the clinical characteristics and outcome of COVID-19 among COVID-19 hospitalized patients [ Time Frame: 7 months ]the impact of previous exposure to different HCV management protocols on the clinical characteristics and outcome of COVID-19 among COVID-19 hospitalized patients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04757272
|Contact: Sherif M Mowafy, MD||01003523374 ext firstname.lastname@example.org|
|Contact: Essamedin M Negm, MD||01280985049 ext email@example.com|